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Introduction
The emergence and spread of antimicrobial resistant
organisms has made it increasingly difﬁcult to treat
serious Gram-positive infections and has dictated the
need to develop new antimicrobial agents. Infections
because of antimicrobial resistant pathogens have
been associated with increased length of stay, health-
care costs, morbidity and mortality (1,2). Studies
have validated the association between increased
mortality among critically ill patients and inappro-
priate antimicrobial selection, with resistance being
the primary reason for inappropriate therapy (3,4).
There have been escalating rates of resistance over
the last two decades, especially among the Gram-
positive pathogens such as Staphylococcus spp.,
enterococci and streptococci. The efﬁcacy of penicill-
inase-resistant penicillins, vancomycin and teicopla-
nin, once the foundation for the treatment of
multidrug resistant Gram-positive pathogens, is chal-
lenged daily.
The development of glycopeptide-resistant patho-
gens was initially identiﬁed in the late 1980s, when
vancomycin-resistant enterococci (VRE) ﬁrst
emerged in hospitals. More recently in 1995,
Staphylococcus aureus strains with increased vanco-
mycin minimum inhibitory concentrations (MICs)
were reported in the USA (5). Soon after, a het-
erogeneous vancomycin-intermediate Staphylococcus
aureus (VISA) strain was identiﬁed in Japan in
1996. In 2002, the ﬁrst vancomycin-resistant
Staphylococcus aureus (VRSA) strain was reported
in the USA. To date, there have been six VRSA
isolates reported worldwide; all six have been
reported in the USA, four of which have been
reported in south-east Michigan (6–12). Vancomy-
cin has long been considered the drug of choice
for the treatment of methicillin-resistant Staphylo-
coccus aureus (MRSA) infections. Its modest efﬁc-
acy, coupled with increasing reports of treatment
failures as a result of elevated vancomycin MICs
seen in a proportionally greater number of isolates,
has made it increasingly important to ﬁnd an
alternative agent which is effective in the treatment
of resistant Gram-positive infections.
Dalbavancin (formerly BI397) is a novel semisyn-
thetic glycopeptide that was engineered to be an
improved alternative to the naturally available glyco-
peptides, vancomycin and teicoplanin. Preliminary
in vitro assays and animal models have demonstrated
it to be more active than vancomycin or teicoplanin
against Gram-positive bacteria. It is anticipated to be
approved by the Food and Drug Administration in
the 1st quarter of 2007.
Mechanisms of action and structure
Dalbavancin is characterised as a second-generation
bactericidal glycopeptide. Other examples of the
glycopeptide class include vancomycin, teicoplanin,
oritavancin (formerly LY-333328) and telavancin
(formerly TD-6424). Like other glycopeptides,
dalbavancin’s mechanism of action involves the
formation of a complex with the C-terminal d-ala-
nyl-d-alanine of growing peptidoglycan chains,
thereby inhibiting bacterial cell wall biosynthesis
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unique ability to dimerise and anchor its lipophi-
lic side chain in the bacterial membranes (14).
This is hypothesised to increase the afﬁnity of
dalbavancin for its target and to increase its anti-
microbial potency. Consequently, dalbavancin pos-
sesses more potent in vitro bactericidal activity
than vancomycin or teicoplanin against many
resistant Gram-positive organisms such as MRSA
(14,15).
Originally developed by Vicuron Pharmaceuticals
Inc., (Fremont, CA, USA) dalbavancin (Figure 1)
was chemically derived from parent compound
A-40926, a naturally occurring teicoplanin-like glyco-
peptide produced by the actinomycete Nonomuria
spp. Modiﬁcations of the parent compound included
derivatization of functional groups such as the C-ter-
minus and N-terminus of the peptide, removal of
sugars and the addition of acyl moieties (15).
Pharmacokinetics
The pharmacokinetics of dalbavancin has been stud-
ied in healthy volunteers, and in renally and hepati-
cally impaired subjects. Early Phase I, II and III
clinical trials were used to determine pharmacokinet-
ic parameters. Immediately following the end of
infusion, maximum concentrations of dalbavancin
are achieved. The drug initially distributes into a vol-
ume of approximately 8–12 l. Dalbavancin exhibits
linear, dose-dependent pharmacokinetics in healthy
adults, following the administration of single intra-
venous doses of dalbavancin 140–1120 mg (Figure 2).
The plasma pharmacokinetic proﬁles are character-
ised by a rapid decline over 12 h during the distribu-
tion phase, followed by a slower terminal elimination
phase. It has a half-life of 170–210 h, making once-
weekly dosing feasible for dalbavancin (16,17).
Total protein binding of dalbavancin is concentra-
tion independent, reversible and estimated to be 93%
(18). Animal studies regarding tissue distribution
have demonstrated tissue concentrations reaching
maximal levels within 24 h, with the highest concen-
trations in the liver and kidneys. Two weeks after
administration of the drug, more than 1% of the
radioactivity was still present in the liver, kidneys,
brown fat, skin and skeletal muscle (19).
Dalbavancin has been administered and studied in
healthy subjects using loading doses of 300–1000 mg
given over 30 min (Figure 3), followed by a dose of
daily 100 mg/day for 6 days (17). In addition, dalba-
vancin has also been evaluated using a two-dose
regimen in clinical trials (1100 mg as a single intra-
venous infusion given over 30 min, or a 1000 mg
loading dose followed by 500 mg intravenously
1 week later) (20).
Plasma concentrations were determined in a Phase
II, randomised, controlled, open-label study of skin
and soft-tissue infections (SSTI) caused by Gram-
positive pathogens. Subjects that received a single
dose of dalbavancin (1100 mg) were able to sustain
total plasma concentrations of 30 lg/ml for approxi-
mately 1 week. Subjects that received 1000 mg on
day 1, followed by 500 mg on day 8 were able to
Figure 1 Chemical structure of dalbavancin
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about 20 days. The dalbavancin plasma concentra-
tions were at least equal to the MIC90 values for
Gram-positive pathogens 12 days after the second
dose, despite the high degree of plasma protein bind-
ing. Following a single 1000 mg dose of dalbavancin,
penetration into blister ﬂuid was 60%. Blister ﬂuid
concentrations of 40 lg/ml are well above the
MIC90s of Gram-positive pathogens, and these con-
centrations are maintained for up to 1 week (21).
Although data evaluating dalbavancin’s activity
against enterococci is scarce, dalbavancin demon-
strates excellent in vitro bactericidal activity against
staphylococci and streptococci (22–26).
Dalbavancin is not a substrate, inducer or inhib-
itor of hepatic cytochrome p450 isoenzymes. Forty
per cent is eliminated via the renal route. Most of
the drug is excreted as intact drug. Concentration
was unchanged in patients with mild renal impair-
ment, but further studies are needed to evaluate
patients with severe renal impairment. In addition,
animal studies have demonstrated that up to 50% of
the dalbavancin is excreted into faeces via bile. Total
drug clearance, which is inﬂuenced by body surface
area and the central volume of distribution, is esti-
mated to be approximately 0.04 l/h in healthy adults.
No adjustments are needed in hepatic insufﬁ-
ciency, as concentrations of the drug do not increase
Figure 2 Mean dalbavancin concentrations in plasma following administration of a single 30-min intravenous infusion
(n ¼ 3 per group) (17)
Figure 3 Mean dalbavancin concentrations in plasma following administration of multiple 30-min intravenous infusion
doses (n ¼ 3 per group) (17)
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gender and serum albumin had no effect on the
pharmacokinetics of dalbavancin in clinical trials. At
this point, it is still unknown if the drug penetrates
the cerebrospinal ﬂuid, or whether the drug is
removed during haemodialysis. However, the high
protein binding of dalbavancin would suggest both
of these scenarios to be unlikely.
In vitro studies
Dalbavancin has a spectrum of activity similar to
other glycopeptides, demonstrating bactericidal activ-
ity against a variety of Gram-positive pathogens
(17,22,29–31). Thus far, dalbavancin appears to be
more active in vitro than either teicoplanin, vanco-
mycin, linezolid or quinupristin/dalfopristin against
all tested Staphylococcus spp. (Tables 1 and 2). In a
recent survey of over 1100 MRSA clinical isolates,
the MIC50 of dalbavancin was 0.06 lg/ml, compared
with 1 lg/ml for vancomycin, and 0.5 lg/ml for tei-
coplanin. Similar activity was demonstrated against
methicillin-resistant coagulase-negative staphylococci
(CoNS) with an MIC90 0.06 lg/ml, compared with
an MIC90 of 2 lg/ml for vancomycin and 4 lg/ml
for teicoplanin. Against isolates with increased MICs
to vancomycin and teicoplanin (glycopeptide inter-
mediate Staphylococcus aureus), dalbavancin demon-
strates an MIC range of 0.06–1 lg/ml (29). Against
linezolid non-susceptible S. aureus, dalbavancin activ-
ity is maintained with MICs ranging from 0.03 to
0.06 lg/ml (31). Dalbavancin has also been shown to
be active against one of the VRSA strains isolated in
the USA (MIC 0.5 lg/ml) (32,33).
In pharmacodynamic studies by Lin et al., dalba-
vancin demonstrated time-kill kinetics against sta-
phylococci that was similar to those of vancomycin
and teicoplanin. It exhibited bactericidal activity after
24 h, at four times the MIC (33).
Against Streptococcus spp., dalbavancin is as active
as teicoplanin and 4–8 times more active than vanco-
mycin with MIC90 values ranging from 0.03 to
0.06 lg/ml. Dalbavancin has also shown lower MICs
for penicillin-resistant and ceftriaxone-resistant iso-
lates of Streptococcus pneumoniae and viridans-group
Streptococci, b-haemolytic Streptococci and Streptococ-
cus agalactiae when compared with the activity of
either vancomycin, teicoplanin, linezolid or quinupr-
istin/dalfopristin (14,30).
Dalbavancin inhibits vancomycin-susceptible and
resistant enterococcal strains, (MIC range: 0.03–
0.12 lg/ml), but has poor activity against vancomy-
cin-resistant (vanA) enterococci (MIC90 value 32 to
> 128 lg/ml). This lack of activity against VRE
strains that contain the vanA gene differentiates dalb-
avancin from the other investigational glycopeptides,
oritavancin and telavancin. Oritavancin and telavan-
cin have a second mechanism of action, the transgly-
cosylation of the peptidoglycan, which appears to
explain their activity against the vanA containing
Enterococci (30). It is unknown why dalbavancin
shows activity against vanA containing VRSA, but
not VRE strains which contain the vanA gene. Poss-
ible differences in cell wall between enterococci and
staphylococci may need to be explored.
Dalbavancin has variable activity against other
pathogens, such as Lactobacillus spp. Its activity
against corynebacteria is comparable with the activity
of vancomycin. It also has potent activity against
some Gram-positive anaerobes and fastidious aerobes
including Actinomyces spp., Propionibacterium spp.,
and Clostriudium spp. excluding Clostridium clostridi-
oforme. Dalbavancin has minimal activity against
Gram-negative bacteria, including Gram-negative
anaerobic bacilli (34).
Susceptibility breakpoints have not yet been estab-
lished for dalbavancin. However, the proposed ranges
are 0.008–0.03 lg/ml for S. pneumoniae and 0.03–
0.12 lg/ml for both Enterococcus faecalis and S. aureus.
In vitro assays have evaluated the potential for
spontaneous generation of resistance in vivo. One-
step resistance assays in S. aureus have not detected
any resistance against dalbavancin. After serial pas-
sage, bacterial populations were more homogeneous
in their susceptibility to dalbavancin than to vanco-
mycin or teicoplanin. Several investigators have con-
cluded that the selection of dalbavancin resistance
might be less likely to develop than resistance in
either teicoplanin or vancomycin (35).
In vitro studies
Dalbavancin has been studied extensively in animal
models and has successfully demonstrated efﬁcacy in
infections caused by MRSA in the rodent pouch
model, against penicillin-resistant S. pneumoniae in
the lobar pneumonia infections model and against
MRSA in the rodent endocarditis model (30,36,37).
A single daily dose of dalbavancin was equal to or
more active than twice the daily dose of either
teicoplanin or vancomycin against staphylococci in
experimental endocarditis in rats and in septicaemia
models in immunocompetent and neutropenic mice.
In addition, dose-dependant killing of MRSA in the
rodent endocarditis model was demonstrated with
the once-daily dalbavancin (10 mg/kg for 4 days)
(30).
Dalbavancin was compared with vancomycin in an
attempt to prevent S. aureus colonisation of devices
in vivo in a rabbit model. While not statistically
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Organism Isolates (n) MIC90 (lg/ml) MIC range (lg/ml)
Staphylococci
Quin/dalfo resistant (38) 8 NA 0.03–0.06
Vancomycin intermediate (38) 10 0.06 0.06–2
Staphylococcus aureus (25,39,40,42) 4243 0.06 £ 0.008–0.5
Methicillin susceptible (25,27,40–44,47,48) 4838 0.06–0.5 £ 0.008–0.5
Methicillin resistant (25,27,40–44,47,48) 2726 0.06–1 £ 0.015–1
Glycopeptide intermediate (25,41) 29 1–2 0.06–16
Linezolid non-susceptible (25) 5 NA 0.03–0.06
Staphylococcus coagulase negative (25,38,40,42) 1775 0.06–0.12 £ 0.008–1
Methicillin susceptible (25,27,40–44,47,48) 682 0.06–0.5 £ 0.008–0.6
Methicillin resistant (25,27,40–44,47,48) 2100 0.06–0.5 £ 0.008–1
Vancomycin non-susceptible (25) 11 1 0.25–2
Teicoplanin resistant (38) 15 0.25 0.03–0.25
Staphylococcus epidermidis
Methicillin susceptible (27,41) 13 0.25–0.5 £ 0.03–0.25
Methicillin resistant (27,41) 12 0.25 £ 0.03–1
Staphylococcus haemolyticus
Methicillin susceptible (27) 10 0.13 £ 0.03–0.25
Methicillin resistant (27) 12 0.5 £ 0.03–4
Streptococcus pneumoniae (25,40,42,44,46) 1422 £ 0.03–0.06 0.004–0.125
Penicillin susceptible (25,27,40,42,48) 1647 0.016–0.06 0.004–0.06
Penicillin non-susceptible (25,27,38,40,42,48) 969* £ 0.016–0.03 £ 0.008–0.25
Ceftriaxone resistant (38) 16 £ 0.016 £ 0.016–0.03
Streptococcus pyogenes (25,27) 211 0.015 £ 0.002–0.06
Erythromycin susceptible (25) 161 0.015 £ 0.002–0.06
Erythromycin resistant (25) 45 0.015 £ 0.002–0.06
Viridans group streptococci (25,40,42,44) 313 0.016–0.03 £ 0.002–0.06
Penicillin susceptible (25,48) 130 0.03 £ 0.002–0.06
Penicillin non-susceptible (25,27,48) 6 0.03 £ 0.008–0.06
Erythromycin susceptible (24) 21 0.03 £ 0.002–0.03
Erythromycin resistant (25) 31 0.03 £ 0.002–0.06
b-Haemolytic streptococci (25,40,42,44,48) 757 0.015–0.06 £ 0.002–0.25
Streptococcus agalactiae (25) 52 0.015 0.008–0.06
Enterococcus spp. (40,42) 2062 0.12–16 £ 0.008 to > 16
Vancomycin susceptible (27,40,42,44) 1606 0.06–0.5 £ 0.008–1
Vancomycin resistant (39,40,42,44) 592 > 16–32 £ 0.015 to > 32
vanA resistant (27,38) 79 32 to > 128 0.03 to > 128
vanB resistant (27,38) 21 0.12–1 0.02–2
Linezolid resistant (39) 9 NA £ 0.015 to > 32
Enterococcus faecalis (48)
Vancomycin susceptible (48) 586 0.06 £ 0.015–4
Vancomycin resistant (38,48) 34 32 £ 0.015 to > 32
Enterococcus faecium
Vancomycin susceptible (48) 77 0.12 £ 0.015–4
Vancomycin resistant (38,48) 92 32 0.03 to > 32
Quin/dalfo resistant (38) 29 0.12–8§ £ 0.016 to > 32
Actinomyces spp. (28) 38 0.5 0.03–0.5
Bacillus spp. (40,44) 25 0.12–0.25 0.016–2
Clostridium spp. (28) 16 0.5 £ 0.015–1
Clostridium difﬁcile (28) 26 0.25 0.125–0.5
Clostridium perfringens (28) 10 0.125 0.03–0.125
Corynebacterium spp. (28,40,44) 51 £ 0.03–0.5 £ 0.015–1
Corynebacterium jeikeium (28,44) 20 0.5 £ 0.03–0.5
Lactobacillus spp. (28) 23 > 32 0.06 to > 32
Listeria spp. (48) NA 0.06 NA
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device colonisation with dalbavancin when compared
with either vancomycin (p ¼ 0.07) or saline (p ¼
0.20) (38).
Animal studies using the granuloma pouch
model were also important in selecting the once a
week dosing in human infections as the most
appropriate dosing interval. Dose-dependent reduc-
tion of bacterial load and prolonged suppression of
regrowth of bacteria were demonstrated. Adminis-
tration of 2.5, 5 and 10 mg/kg dosages of dalbavan-
cin were administered. No reduction of MRSA
bacterial load was observed following the adminis-
tration of 2.5 mg/kg. A 1 log10 cfu/ml reduction in
bacterial load was observed following the adminis-
tration of 5 mg/kg, and a > 2 log10 cfu/ml reduc-
tion was seen following the administration of
10 mg/kg. In addition, bacterial regrowth was
inhibited for more than 96 h following treatment
with dalbavancin (37).
Clinical efﬁcacy
Two open-label, Phase II clinical trials have been
published. Seltzer et al. (20,39) compared once-
weekly dalbavancin vs. standard-of-care antimicro-
bial therapy for the treatment of SSTI. In this
study, patients with a creatinine clearance of
<50 ml/min, self-limited infections, compromised
vascularity, documented osteomyelitis or glycopep-
tide hypersensitivity were excluded. Sixty-two adult
patients were enrolled and randomly assigned to
receive one of three treatment arms: dalbavancin
1100 mg as a single i.v. infusion, dalbavancin
1000 mg i.v., followed by 500 mg i.v. 1 week later,
or a deﬁned standard of care antimicrobial (ﬁrst
generation cephalosporin, piperacillin/tazobactam,
clindamycin, vancomycin or linezolid, alone or in
combination). Patients were allowed to receive addi-
tional Gram-negative aerobic or anaerobic coverage
if deemed necessary.
The majority of patients had a documented diag-
nosis of either a deep or complicated infection
(> 90%) and most had infections that required
surgical drainage (70%). Forty-one (66.1%) patients
had one or more pathogens detected at baseline
cultures. S. aureus was the most prevalent organism
(34/41 pts; 83%), 50% of the S. aureus were MRSA
in the dalbavancin group, compared with 20% in the
comparator group. Although the numbers are small,
analysis of 51 clinically evaluable patients demonstra-
ted clinical success in 16 of 17 (94%) patients treated
with two doses of dalbavancin, eight of 13 (62%)
treated with one dose of dalbavancin, and 16 of 21
(76%) patients treated with the comparator. The
two-dose dalbavancin arm appeared to demonstrate
a more favourable response in patients infected with
MRSA. Eradication rates of S. aureus among micro-
biologically evaluable patients were higher in the
two-dose dalbavancin group (90%; 9/10 pts.) than in
the one-dose dalbavancin group (50%; 5/10 pts.) or
in the comparator (60%; 6/10 pts). This suggested
that the two-dose regimen of dalbavancin, adminis-
tered 1 week apart, appears to be more effective than
the single-dose dalbavancin or the comparator regi-
men in the treatment of complicated Gram-positive
SSTIs. However, because of the study’s small sample
size, statistical analysis was not performed (39).
In a second study, Raad et al. (40) conducted a
Phase II, open-label, randomised, multicentre clinical
trial evaluating dalbavancin vs. vancomycin in adult
patients with catheter-related bloodstream infections
(CR-BSIs). Dalbavancin was administered as a
1000 mg intravenous loading dose, followed by a
500 mg intravenous dose 1 week later and compared
with a 14-day course of intravenous vancomycin at
1000 mg twice daily. Catheter removal was required
in all instances of conﬁrmed S. aureus infections. For
CoNS, management was at the discretion of the
investigator, although catheter removal was recom-
mended. Of the 54 isolates in the 51 patients, the
most common pathogens identiﬁed in the conﬁrmed
Table 1 (Continued)
Organism Isolates (n) MIC90 (lg/ml) MIC range (lg/ml)
Micrococcus spp. (40) 13 0.03 £ 0.008–0.03
Peptostreptococcus spp. (28) 30 0.25 £ 0.015–0.5
Propionibacterium spp. (28) 15 0.5 0.03–0.5
Permission for reprint granted by Ann Pharmocother; 2006; 40: 449–60. *Includes penicillin-non-susceptible, penicillin-intermediate and
penicillin-resistant isolates. Includes penicillin-non-susceptible and penicillin-resistant isolates. vanA negative isolates. §vanA positive
isolates. MIC, minimum inhibitory concentration; NA, not available; quin/dalfo, quinupristin/dalfopristin; vanA, vancomycin-resistant
enterococci possessing the vanA gene.
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Organism
MIC90 range (lg/ml)*
Dalbavancin Vancomycin Linezolid Teicoplanin Quin/dalfo Daptomycin
Staphylococcus aureus (25,40,42) 0.06 1 £ 2 2 0.5 NA
Methicillin susceptible (25,27,41,43,44,47,48) 0.06–0.5 1 1–4 2–4 0.25–0.5 0.5
Methicillin resistant (25,27,41,43,44,47,48) 0.06–1 1–4 0.5–8 2–4 0.5 0.5
Glycopeptide intermediate (25,39,41) 1–2 8 8–16 2 1 NA
Staphylococcus coagulase negative (25,40,42) 0.06–0.12 2 4–8 1–2 0.5 NA
Methicillin susceptible (25,27,43,44,47,48) 0.06–0.5 2 2–8 1–2 0.25–0.5 0.5
Methicillin resistant (25,27,43,44,47,48) 0.06–0.5 2–4 2–16 1–2 0.5–1 0.5
Vancomycin non-susceptible (25) 1 8 > 32 2 0.5 NA
Teicoplanin resistant (39,45) 0.25 2 NA 1 1 NA
Staphylococcus epidermidis
Methicillin susceptible (27,41) 0.25–0.5 1–2 8 NA NA NA
Methicillin resistant (27,41) 0.25 2–4 16 NA NA NA
Staphylococcus haemolyticus
Methicillin susceptible (27) 0.13 2 32 NA NA 2
Methicillin resistant (27) 0.5 4 32 NA NA NA
Streptococcus pneumoniae (25,40,42,44,46) < 0.03–0.06 0.5 0.125 to £ 2 1–2 < 0.5–1 NA
Penicillin susceptible (25,27,48) 0.03–0.06 0.5 0.06 1 0.5 NA
Penicillin non-susceptible (25,27,38,48) £ 0.016–0.03 0.5 0.06 1 0.5–1 NA
Streptococcus pyogenes (25) 0.015 0.5 0.06 1 £ 0.12 NA
Erythromycin susceptible (25) 0.015 0.5 0.06 1 £ 0.12 NA
Erythromycin resistant (25) 0.015 0.5 0.06 1 £ 0.12 NA
Viridans group streptococci (25,40,42,44) 0.016–0.03 1 £ 2 1 0.5–1 NA
Penicillin susceptible (25,48) 0.03 1 0.06 1 1 NA
Penicillin non-susceptible (25,48) 0.03 0.5–1 0.12 1 1 NA
Erythromycin susceptible (25) 0.03 1 0.06 1 1 NA
Erythromycin resistant (25) 0.03 1 0.12 1 1 NA
b-Haemolytic streptococci (25,40,42,44,48) 0.015–0.06 0.5 £ 2 1 0.5 NA
Streptococcus agalactiae (25) 0.015 0.5 0.12 1 0.25 NA
Enterococcus spp. (40,42) 0.12–16 2 to > 16 £ 2 to > 16 2 > 2 NA
Vancomycin susceptible (44) 0.5 2 0.5 NA > 8 NA
Vancomycin resistant (44) 32 > 16 > 16 NA > 8 NA
vanA resistant (27,38) 32 to > 128 > 128 > 128 NA NA NA
vanB resistant (27) 0.12–1 128 £ 22 8 N A
Enterococcus faecalis
Vancomycin susceptible (48) 0.06 NA 0.5 2 > 8 NA
Vancomycin resistant (38,48) 32 NA > 16 2 > 8 NA
Enterococcus faecium
Vancomycin susceptible (48) 0.12 NA 0.5 2 2 NA
Vancomycin resistant (38,48) 32 NA > 16 2 1 NA
Quin/dalfo resistant (38) 0.12§–8– NA NA 2 NA NA
Actinomyces spp. (28) 0.5 1 NA 1 0.25 16
Bacillus spp. (44) 0.25 1 2 NA 2 NA
Clostridium spp. (28) 0.5 2 NA 4 0.5 8
Clostridium difﬁcile (28) 0.25 2 NA 8 4 2
Clostridium perfringens(28) 0.125 0.5 NA 2 0.5 1
Corynebacterium spp.(28,44,48) £ 0.03–0.5 0.5–1 0.5 1 0.5–1 8
Corynebacterium jeikeium (28) 0.5 0.5 NA 0.5 0.5 0.25
Lactobacillus spp. (48) > 32 > 32 NA 8 2 > 32
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(26 isolates), S. aureus (23 isolates, of which 14 were
MRSA) and E. faecalis (ﬁve isolates). MRSA was
encountered more frequently among isolates in the
vancomycin group, nine of 28 (32%), than in the
dalbavancin group, ﬁve of 26 (19.2%). In the micro-
ITT population, overall success rates, deﬁned as the
sum of clinical and microbiological success were
assessed 18–24 days after the end of therapy. Dalba-
vancin was superior to vancomycin (p < 0.05) in the
microITT population (87% success in the dalbavan-
cin group vs. 50% in the vancomycin group). How-
ever, the small number of patients with MRSA
infection who received dalbavancin renders it difﬁ-
cult to evaluate the signiﬁcance of these numbers
(40).
Three Phase III clinical trials have been comple-
ted evaluating dalbavancin in patients with both
uncomplicated or complicated skin and skin struc-
ture infections (SSSIs). The New Drug Application
(NDA), which was submitted in December, 2004,
included results from all three of these clinical tri-
als and included more than 1850 subjects. The
results of two of these Phase III trials were recently
presented in abstract form (41). In both the phase
III clinical trials, each trial met the primary and
secondary end-points of non-inferiority when com-
pared with linezolid, cefazolin or vancomycin, three
commonly used agents for SSSIs. The most
common pathogen isolated in these studies was
S. aureus.
In a recently published Phase III trial, Juregui
et al. (42) compared once-weekly dalbavancin vs.
twice-daily linezolid for the treatment of complicated
SSSIs. Eight hundred ﬁfty-four patients were rand-
omised in a double-blind manner (ratio 2 : 1) to
receive either dalbavancin (1000 mg administered
intravenously on day 1 and 500 mg intravenously on
day 8) or linezolid (600 mg administered intraven-
ously or orally every 12 h for 14 days). MRSA was
identiﬁed in 51% of patients from whom a pathogen
was isolated at baseline. Dalbavancin and linezolid
demonstrated comparable clinical efﬁcacy in the clin-
ically evaluable population at the test-of-cure visit
(88.9% and 91.2% success respectively). The rate of
clinical success at the end of therapy was > 90% in
both arms. Less than 1.0% of patients in either treat-
ment arm experienced a relapse after the test-of-cure
visit. In the microbiologically evaluable patients,
microbiological success rates for dalbavancin (89.5%)
and linezolid (87.5%) were comparable at the test-
of-cure visit. The study met its objective of non-
inferiority and demonstrated that two doses of
dalbavancin (1000 mg given on day 1 followed by
500 mg given on day 8) were as effective as linezolid
given twice daily for 14 days for the treatment of
patients with complicated SSSI, including those
infected with MRSA (42).
In another Phase III clinical trial, 565 patients
were enrolled into the study comparing dalbavancin
vs. intravenous cefazolin, followed by oral cephalexin
for the treatment of uncomplicated SSSIs. The
primary end-point was clinical response at the fol-
low-up visit in the evaluable patient population.
Evaluable patients on either dalbavancin or cefazolin
demonstrated an 89.1% response vs. an 89.1%
response [95% conﬁdence interval (CI); )6.8, 6.8].
In the ITT group, patients on dalbavancin patients
showed a 76.0% response rate vs. a 75.8% response
rate for those patients receiving cefazolin (95% CI;
)7.7, 8.2) (41).
A third Phase III clinical trial was conducted in
patients suffering from SSSIs suspected or conﬁrmed
to be caused by MRSA. The study was a controlled,
open-labelled study and enrolled 156 patients.
Patients were randomised to either dalbavancin or
vancomycin. Evaluable patients on the dalbavancin
arm demonstrated an 89.9% response rate, compared
Table 2 (Continued)
Organism
MIC90 range (lg/ml)*
Dalbavancin Vancomycin Linezolid Teicoplanin Quin/dalfo Daptomycin
Listeria spp. (40) 0.06 NA NA NA NA NA
Peptostreptococcus spp. (28) 0.25 0.5 NA 2 0.5 1
Propionibacterium spp. (28) 0.5 1 NA 1 0.2 16
Permission for reprint granted by Ann Pharmocother; 2006; 40: 449–60. *MIC90 range based on MIC90 values reported in different studies that compared
dalbavancin with at least one of the comparator agents. Data from Ref. (27) includes other coagulase-negative staphylococci, but do not include Staphylococcus
epidermidis and Staphylococcus haemolyticus. Includes penicillin-non-susceptible, penicillin-intermediate and penicillin-resistant isolates. §vanA negative isolates.
–vanA positive isolates. MICs, minimum inhibitory concentrations; NA, not available; quin/dalfo, quinupristin/dalfopristin; vanA, vancomycin-resistant enterococci
possessing the vanA gene.
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CI; )13.0, 19.4). In the ITT group, patients that
received dalbavancin demonstrated an 86.0%
response rate vs. a 65.3% response rate for vancomy-
cin (95% CI; 4.3, 37.0) (41).
Safety and tolerability
Dalbavancin appears to be well tolerated in animal
studies, Phase I, II and III clinical trials. At this time,
there is no evidence of dose or duration-related toxi-
cities. In randomised, double-blind, placebo-con-
trolled, single- and multiple-dose, dose-escalation
studies in healthy adult male and female subjects,
dalbavancin was well tolerated without serious
adverse events or deaths. In the clinical trials thus
far, adverse events have been reported in 67% of
subjects and classiﬁed as mild in severity. The most
commonly reported adverse events included pyrexia
(50%), headache (25%) and nausea (6%) (19). In
clinical trials thus far, subjects receiving placebo
reported similar rates of pyrexia (38%) and head-
aches (31%). Laboratory ﬁndings, physical examina-
tions and electrocardiograms were unchanged from
baseline. No auditory or vestibular toxicity was
observed in those patients who received dalbavancin
dosages as high as 1120 mg or cumulative doses of
1600 mg administered over a 1-week period, respect-
ively (43).
In a separate clinical trial published by Seltzer
et al. (39), 62 subjects treated for SSTIs reported
drug-related adverse events in 11/20 (55%) patients
who received a single dose (1100 mg) of dalbavancin,
10/21 (48%) patients who received two doses
(1000 mg on day 1 and 500 mg on day 8) of dalba-
vancin, and in 12/21 (57%) patients who received a
comparator regimen. Laboratory data was unchanged
from baseline. In 33 patients with CR-BSIs who
received dalbavancin (1000 mg on day 1 and 500 mg
on day 8) in the study reported by Raad et al. (40),
the most commonly reported, drug-related adverse
events were oral candidiasis (12.1%; n ¼ 4), diar-
rhoea (21.2%; n ¼ 7), constipation (18.2%; n ¼ 6)
and pyrexia (18.2%; n ¼ 6). There were no study
withdraws or discontinuation of dalbavancin because
of any adverse events.
The safety proﬁle reported from the only pub-
lished Phase III clinical trial also corroborates the rel-
atively good safety proﬁle previously demonstrated
by dalbavancin in its other clinical trials (Table 3).
Juregui et al. (42) reported the ﬁndings of 854
patients that were randomised to receive either dalb-
avancin or linezolid for the treatment of complicated
SSSIs. Overall, the study doses were well tolerated
with relatively few side effects. The type and severity
of adverse events were comparable between the two
groups. Adverse events were more commonly repor-
ted in the linezolid group (32.2%) than in the dalba-
vancin group (25.4%). Gastrointestinal symptoms
(e.g. nausea 3.2%, diarrhoea 2.5% and vomiting
1.9%) were the most commonly reported adverse
events. There were no cases of red man syndrome
reported and few reports of infusion site reactions.
Discontinuation rates for each group were similar,
3.9% for dalbavancin and 3.2% for linezolid. Three
serious adverse events were reported. One patient in
the dalbavancin group developed mild leucopenia
which resolved spontaneously. Two patients in the
linezolid group experienced a severe adverse event,
one patient developed moderate thrombocytopenia,
which resolved spontaneously, and one patient devel-
oped severe pancytopenia which resolved with treat-
ment.
Drug–drug interactions
Dalbavancin does not appear to be metabolised by
the cytochrome P450 enzyme system. The adminis-
tration of cytochrome P450 substrates, inhibitors or
inducers do not affect dalbavancin’s clearance rates.
No drug–drug interactions have been identiﬁed. Fur-
thermore, it is unknown whether dalbavancin has
any cross-reactivity with glycopeptides as patients
with a history of hypersensitivity have been excluded
from these clinical trials. Recently, the in vitro drug
Table 3 Adverse events with dalbavacin Phase III
clinical trial of 854 patients (42)
Adverse event
Percentage of patients
Dalbavancin
arm (n ¼ 571)
Linezolid
arm (n ¼ 283)
Any event 25.4 32.2
Nausea 3.2 5.3
Diarrhoea 2.5 5.7
Elevated blood lactate
dehydrogenase level
1.9 1.8
Headache 1.9 1.8
Elevated – c
glutamyltransferase level
1.9 1.4
Vomiting 1.9 1.1
Rash 1.8 1.8
Abnormal liver
function test results
1.6 1.1
Elevated alanine
aminotransferase level
1.2 1.8
Fungal vaginosis 0.9 1.8
Loose stools 0.4 2.1
Thrombocytopenia 0.2 2.5
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nine different antimicrobial agents (clindamycin,
daptomycin, gentamicin, levoﬂoxacin, linezolid, oxa-
cillin, quinupristin/dalfopristin, rifampin and vanco-
mycin) was evaluated for either synergistic or
antagonistic interactions. Antagonism was not
observed between dalbavancin and any of the nine
antimicrobials tested. In addition, there was no evi-
dence of synergy observed between gentamicin and
dalbavancin. However, dalbavancin and oxacillin
appear to have some degree of synergy or partial
synergy against staphylococci, including methicillin-
resistant strains, VISA and enterococci. Further test-
ing is needed to determine the clinical signiﬁcance of
these ﬁndings (44).
Conclusions
The increase in infections because of the Gram-posit-
ive organisms has been described worldwide and
across all age groups. Recent outcome studies have
demonstrated that a Gram-positive infection may
increase the hospital length of stay from 7 to
28 days, thus adding to the rising cost of healthcare.
In part, the increasing cost of hospitalisation is fre-
quently for the administration of parenteral antimi-
crobial agents. Dalbavancin is a novel second
generation glycolipopeptide, with excellent activity
against a broad spectrum of Gram-positive organ-
isms, including some of the more resistant strains
(45–47). Furthermore, dalbavancin’s uniqueness is its
novel pharmacokinetic proﬁle with a half-life of
170–210 h, which makes the once-weekly dosing
optimal. In general, three Phase III studies in sub-
jects with SSTI have been completed. One large,
pivotal Phase III study in patients with complicated
SSTI demonstrated comparable clinical efﬁcacy vs.
linezolid.
Dalbavancin’s unique half-life, as well as its excel-
lent activity against Gram-positive organisms, should
provide a valuable and economical addition to the
current antimicrobial armamentarium used to man-
age infections because of Gram-positive pathogens.
As a new agent dalbavancin should be used judi-
ciously, where a clinical or cost beneﬁt would be
anticipated. Possible clinical use of dalbavancin for
the treatment of SSSIs and other approved indica-
tions could include the following: patients seen in
the emergency department that do not require hospi-
tal monitoring, completion of inpatient therapy to
allow for earlier hospital discharge, patients in whom
medical compliance would be an issue, and certain
parenteral home-therapy cases. Further studies will
need to be performed to determine whether dalba-
vancin may prove to be a useful alternative to paren-
teral antimicrobials that are currently used to
treat infections that necessitate long courses of
therapy such as endocarditis, septic arthritis or osteo-
myelitis.
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